XenoPort, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1999-01-01

Employees: 251

Market Cap: -

Website: http://xenoport.com

Clinical Trials

A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects

Phase 2

Completed

Conditions: Parkinson's Disease

Interventions: Drug: XP21279 and carbidopa (experimental)
Drug: Sinemet (comparator)
Drug: Placebo for XP21279 and carbidopa
Drug: Placebo for Sinemet

First Posted Date: 2010-07-28

Last Posted Date: 2021-02-18

Lead Sponsor: XenoPort, Inc.

Target Recruit Count: 35

Registration Number: NCT01171313

Locations: 🇺🇸
XenoPort Clinical Site, Houston, Texas, United States

A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)

Phase 2

Completed

Conditions: Gastroesophageal Reflux Disease

Interventions: Drug: arbaclofen placarbil-Cohort 1
Drug: arbaclofen placarbil-Cohort 2
Drug: arbaclofen placarbil-Cohort 4
Drug: arbaclofen placarbil-Cohort 3
Drug: Placebo-Cohort 5
Drug: PPI

First Posted Date: 2009-09-16

Last Posted Date: 2021-02-21

Lead Sponsor: XenoPort, Inc.

Target Recruit Count: 460

Registration Number: NCT00978016

An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects

Phase 1

Completed

Conditions: Parkinson's Disease

Interventions: Drug: Sinemet 25-100 Oral Tablet
Drug: XP21279
Drug: Carbidopa Pill

First Posted Date: 2009-06-05

Last Posted Date: 2021-05-05

Lead Sponsor: XenoPort, Inc.

Target Recruit Count: 14

Registration Number: NCT00914602

Locations: 🇺🇸
XenoPort Investigational Site, Bingham Farms, Michigan, United States

Relative Bioavailability Study for GSK1838262 (Gabapentin Enacarbil)

Phase 1

Completed

Conditions: Pharmacokinetics
Healthy Volunteer

Interventions: Drug: open label

First Posted Date: 2009-02-02

Last Posted Date: 2013-05-14

Lead Sponsor: XenoPort, Inc.

Target Recruit Count: 16

Registration Number: NCT00833391

Locations: 🇺🇸
GSK Investigational Site, Evansville, Indiana, United States

A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms

Phase 2

Completed

Conditions: Back Pain

Interventions: Drug: Arbaclofen placarbil, 20 mg
Drug: Arbaclofen placarbil, 30 mg
Drug: Placebo
Drug: Arbaclofen placarbil, 40 mg

First Posted Date: 2009-01-07

Last Posted Date: 2021-02-21

Lead Sponsor: XenoPort, Inc.

Target Recruit Count: 161

Registration Number: NCT00817986

Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance

Phase 3

Completed

Conditions: Restless Legs Syndrome
Restless Legs Syndrome (RLS)

Interventions: Drug: Placebo
Drug: GSK1838262 Extended Release Tablets

First Posted Date: 2008-09-08

Last Posted Date: 2013-07-22

Lead Sponsor: XenoPort, Inc.

Target Recruit Count: 136

Registration Number: NCT00748098

Locations: 🇺🇸
GSK Investigational Site, Walla Walla, Washington, United States

Prevention Study in Adult Patients Suffering From Migraine Headaches

Phase 2

Completed

Conditions: Migraine Disorders
Migraine

Interventions: Drug: Placebo
Drug: GSK1838262

First Posted Date: 2008-08-27

Last Posted Date: 2013-07-22

Lead Sponsor: XenoPort, Inc.

Target Recruit Count: 526

Registration Number: NCT00742209

Locations: 🇨🇦
GSK Investigational Site, Quebec, Canada

A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN)

Phase 2

Completed

Conditions: Neuropathy, Diabetic

Interventions: Drug: Placebo
Drug: Pregabalin
Drug: GEn 2400mg/day
Drug: GEn 1200mg/day
Drug: GEn 3600mg/day

First Posted Date: 2008-03-26

Last Posted Date: 2013-07-22

Lead Sponsor: XenoPort, Inc.

Target Recruit Count: 421

Registration Number: NCT00643760

Locations: 🇺🇸
GSK Investigational Site, Vancouver, Washington, United States

A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)

Phase 2

Completed

Conditions: Neuralgia, Postherpetic

Interventions: Drug: Placebo
Drug: GEn 1200mg/day
Drug: GEn 2400mg/day
Drug: GEn 3600mg/day

First Posted Date: 2008-02-21

Last Posted Date: 2013-07-22

Lead Sponsor: XenoPort, Inc.

Target Recruit Count: 376

Registration Number: NCT00619476

Locations: 🇨🇦
GSK Investigational Site, Quebec, Canada

A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment

Phase 2

Completed

Conditions: Neuralgia, Postherpetic

Interventions: Drug: GEn 1200mg/day
Drug: GEn 3600mg/day

First Posted Date: 2008-02-18

Last Posted Date: 2013-07-22

Lead Sponsor: XenoPort, Inc.

Target Recruit Count: 96

Registration Number: NCT00617461

Locations: 🇩🇪
GSK Investigational Site, Berlin, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy